Incidence of Gastrointestinal Perforations in Patients with Rheumatoid Arthritis Treated with Tocilizumab from Clinical Trial, Postmarketing, and Real-World Data Sources.

Monemi, Sharareh; Berber, Erhan; Sarsour, Khaled; Wang, Jianmei; Lampl, Kathy; Bharucha, Kamal; Pethoe-Schramm, Attila

Monemi, Sharareh; Berber, Erhan; Sarsour, Khaled; Wang, Jianmei; Lampl, Kathy; Bharucha, Kamal; Pethoe-Schramm, Attila.

Afiliação

Monemi S; Genentech, Inc., South San Francisco, CA, USA. monemis@gene.com.
Berber E; Genentech, Inc., South San Francisco, CA, USA.
Sarsour K; Genentech, Inc., South San Francisco, CA, USA.
Wang J; Roche Products Ltd., Welwyn Garden City, Hertfordshire, UK.
Lampl K; Genentech, Inc., South San Francisco, CA, USA.
Bharucha K; Genentech, Inc., South San Francisco, CA, USA.
Pethoe-Schramm A; F. Hoffmann-La Roche, Basel, Switzerland.

Rheumatol Ther ; 3(2): 337-352, 2016 Dec.

Article em En | MEDLINE | ID: mdl-27747579

Palavras-chave

Gastrointestinal perforation; Rheumatoid arthritis; Tocilizumab

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Incidence_studies / Risk_factors_studies Idioma: En Revista: Rheumatol Ther Ano de publicação: 2016 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google